Detalhe da pesquisa
1.
Integrated safety analysis of filgotinib treatment for rheumatoid arthritis in patients from Japan over a median of 1.5 years.
Mod Rheumatol
; 33(1): 64-72, 2023 Jan 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35365828
2.
Safety and efficacy of filgotinib for Japanese patients with RA and inadequate response to MTX: FINCH 1 52-week results and FINCH 4 48-week results.
Mod Rheumatol
; 33(4): 668-679, 2023 Jul 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35920102
3.
Long-term safety and efficacy of filgotinib treatment for rheumatoid arthritis in Japanese patients naïve to MTX treatment (FINCH 3).
Mod Rheumatol
; 33(4): 657-667, 2023 Jul 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35921235
4.
Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years.
Ann Rheum Dis
; 81(2): 184-192, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34740884
5.
Exposure-response relationships for the efficacy and safety of filgotinib and its metabolite GS-829845 in subjects with rheumatoid arthritis based on phase 2 and phase 3 studies.
Br J Clin Pharmacol
; 88(7): 3211-3221, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35072287
6.
Efficacy and safety of filgotinib in Japanese patients with refractory rheumatoid arthritis: Subgroup analyses of a global phase 3 study (FINCH 2).
Mod Rheumatol
; 32(1): 59-67, 2022 01 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33274687
7.
Efficacy and safety of filgotinib in combination with methotrexate in Japanese patients with active rheumatoid arthritis who have an inadequate response to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 1).
Mod Rheumatol
; 32(2): 263-272, 2022 Feb 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-34910188
8.
Efficacy and safety of filgotinib alone and in combination with methotrexate in Japanese patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 3).
Mod Rheumatol
; 32(2): 273-283, 2022 Feb 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-34910203
9.
Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial.
Ann Rheum Dis
; 80(7): 848-858, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33504485
10.
Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial.
Ann Rheum Dis
; 80(6): 727-738, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33452004
11.
PTPN14 phosphatase and YAP promote TGFß signalling in rheumatoid synoviocytes.
Ann Rheum Dis
; 78(5): 600-609, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30808624
12.
Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial.
JAMA
; 322(4): 315-325, 2019 07 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-31334793
13.
TGFß responsive tyrosine phosphatase promotes rheumatoid synovial fibroblast invasiveness.
Ann Rheum Dis
; 75(1): 295-302, 2016 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-25378349
14.
Phosphoinositide 3-kinase δ regulates migration and invasion of synoviocytes in rheumatoid arthritis.
J Immunol
; 192(5): 2063-70, 2014 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-24470496
15.
Novel phosphoinositide 3-kinase δ,γ inhibitor: potent anti-inflammatory effects and joint protection in models of rheumatoid arthritis.
J Pharmacol Exp Ther
; 348(2): 271-80, 2014 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-24244039
16.
Protein tyrosine phosphatase expression profile of rheumatoid arthritis fibroblast-like synoviocytes: a novel role of SH2 domain-containing phosphatase 2 as a modulator of invasion and survival.
Arthritis Rheum
; 65(5): 1171-80, 2013 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-23335101
17.
Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis.
Immunol Rev
; 233(1): 233-55, 2010 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-20193003
18.
PI3 kinase δ is a key regulator of synoviocyte function in rheumatoid arthritis.
Am J Pathol
; 180(5): 1906-16, 2012 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-22433439
19.
Benefit of Filgotinib, a JAK1 Preferential Inhibitor, in Rheumatoid Arthritis Patients with Previous Rapid Radiographic Progression: Post Hoc Analysis of Two Trials.
Rheumatol Ther
; 10(1): 161-185, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36327094
20.
Efficacy and Safety of Filgotinib in Patients with High Risk of Poor Prognosis Who Showed Inadequate Response to MTX: A Post Hoc Analysis of the FINCH 1 Study.
Rheumatol Ther
; 10(1): 53-70, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36209441